MetaCap

Zhengye Biotechnology Holding Limited Class A (ZYBT)

NASDAQ: ZYBTHealth CareBiotechnology: Pharmaceutical PreparationsUSD

1.48-0.04 (-2.63%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

ZYBT stock chart

Technical analysis

Key statistics

All statistics
Market cap
$70.14M
EPS (TTM)
-$0.20
52-week range
0.616 – 8.01
Day range
1.45 – 1.51
Volume / Avg
10.50K / 569.22K
Beta
—

52-week range

$0.616$8.01

ZYBT stock today

Shares of Zhengye Biotechnology (ZYBT) finished lower on Nov 20 at $1.48, a drop of 2.63% or $0.04 per share, versus the S&P 500's 3.70% decline. Trading was light, with 10.50K shares changing hands, about 2% of the average daily volume. Shares are 81.5% below their 52-week high of $8.01, set on Jul 20, 2026 and 140.3% above the 52-week low of $0.616, near the bottom of the past year's range.

ZYBT is up 28.7% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 30.8%. Zhengye Biotechnology has posted a net loss over the last twelve months (EPS of -$0.20), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Zhengye Biotechnology

Company profile

Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in the People's Republic of China. The company offers vaccines for swine, cattle, goats, sheep, poultry, and dogs, as well as monovalent vaccine, polyvalent vaccine, combined vaccine, and combined and polyvalent vaccine. It also develops vaccines for household animals, including rabies vaccine and Strain Flury LEP for dogs.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Songlin Song
Headquarters
Jilin
Employees
269
IPO year
2025

Financial highlights

Full financials

In fiscal 2025, Zhengye Biotechnology generated $16.6 million in revenue, down 34.8% from fiscal 2024, the first decline in the 2 years shown. Zhengye Biotechnology reported a net loss of $10.0 million, compared with net income of $1.6 million a year earlier. Gross margin was 20.5% (down from 49.0%) and operating margin -60.6%.

Zhengye Biotechnology annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024
Revenue$16.64M$25.53M
Growth-34.83%—
Net income$-9.98M$1.55M
EPS (diluted)—$0.03

ZYBT news

All ZYBT news

Zhengye Biotechnology peers

Health Care sector
ZYBT peer companies
CompanyPrice% ChgMarket capCompare
COYACoya Therapeutics Inc.2.95-1.01%$69.20Mvs ZYBT
MAIAMAIA Biotechnology Inc.1.11-2.63%$68.54Mvs ZYBT
CINGCingulate Inc.4.51-14.26%$67.48Mvs ZYBT
MNOVMedicinova Inc1.31+3.15%$67.11Mvs ZYBT
PLYXPolaryx Therapeutics Inc.1.33-11.92%$66.30Mvs ZYBT
PMVPPMV Pharmaceuticals Inc.0.876-33.13%$66.17Mvs ZYBT
GOSSGossamer Bio Inc.10.72-4.54%$65.57Mvs ZYBT
FBIOFortress Biotech Inc.1.90+7.34%$64.11Mvs ZYBT

Indexes, lists and sector

Zhengye Biotechnology stock FAQ

What is Zhengye Biotechnology's stock price today?

ZYBT last traded at $1.48 as of Nov 20, 4:00 PM EST, down 2.63% on the day. Prices are delayed at least 15 minutes.

Who is Zhengye Biotechnology's CEO?

Mr. Songlin Song is the chief executive officer of Zhengye Biotechnology Holding Limited Class A, which has about 269 employees.

What is the ZYBT 52-week high?

The 52-week high for ZYBT is $8.01 and the 52-week low is $0.616. The stock is currently 81.5% below its high.

Compare ZYBT